中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

文献类型:期刊论文

AuthorXu, Chunwei48,49; Si, Lu50; Wang, Wenxian51; Li, Ziming52; Song, Zhengbo51; Wang, Qian53; Liu, Aijun54; Yu, Jinpu55; Fang, Wenfeng56; Zhong, Wenzhao57
SourceTHORACIC CANCER
Issued Date2022-09-20
Keywordfusion precision medicine solid tumor targeted therapy tyrosine receptor kinase
ISSN1759-7706
DOI10.1111/1759-7714.14644
Corresponding AuthorZhang, Xiaotian(zhangxiaotianmed@163.com) ; Song, Yong(yong.song@nju.edu.cn) ; Lu, Yuanzhi(yuanzhi.lu@jnu.edu.cn)
English AbstractGene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first "tumor agnostic" drugs approved for pan-cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second-generation drugs designed to overcome first-generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription-polymerase chain reaction, and (DNA and/or RNA-based) next-generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first- and second-generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors.
WOS KeywordINFANTILE FIBROSARCOMA ; MESOBLASTIC NEPHROMA ; MOLECULAR-DETECTION ; ANCHORED MULTIPLEX ; KINASE ; EXPRESSION ; MUTATIONS ; FAMILY ; INHIBITION ; RECEPTORS
WOS Research AreaOncology ; Respiratory System
Language英语
WOS IDWOS:000855706000001
PublisherWILEY